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Abstract
Background: The mechanism for maintaining telomere integrity is controlled by telomerase, a
ribonucleoprotein enzyme that specifically restores telomere sequences, lost during replication by
means of an intrinsic RNA component as a template for polymerization. Among the telomerase
subunits, hTERT (human telomerase reverse transcriptase) is expressed concomitantly with the
activation of telomerase. The role of estrogens and their receptors in the transcriptional regulation
of hTERT has been demonstrated. The current study determines the possible association between
telomerase activity, the expression of both molecular forms of estrogen receptor (ERα and ERβ)
and the protein bcl-2, and their relative associations with clinical parameters.
Methods: Tissue samples from 44 patients with breast cancer were used to assess telomerase
activity using the TRAP method and the expression of ERα, ERβ and bcl-2 by means of
immunocytochemical techniques.
Results: Telomerase activity was detected in 59% of the 44 breast tumors examined. Telomerase
activity ranged from 0 to 49.93 units of total product generated (TPG). A correlation was found
between telomerase activity and differentiation grade (p = 0.03). The only significant independent
marker of response to treatment was clinical stage. We found differences between the frequency
of expression of ERα (88%) and ERβ (36%) (p = 0.007); bcl-2 was expressed in 79.5% of invasive
breast carcinomas. We also found a significant correlation between low levels of telomerase
activity and a lack of ERβ expression (p = 0.03).
Conclusion: Lower telomerase activity was found among tumors that did not express estrogen
receptor beta. This is the first published study demonstrating that the absence of expression of ERβ
is associated with low levels of telomerase activity.
Background
The mechanism for maintaining telomere integrity is con-
trolled by telomerase, a ribonucleoprotein enzyme that
specifically restores telomere sequences lost during repli-
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cation by means of an intrinsic RNA component as a tem-
plate for polymerization. Telomerase has 2 core
functional components that are required for its activity
the catalytic subunit of human telomerase reverse tran-
scriptase (hTERT), and a telomerase RNA template (hTR).
It is activated in most immortal cell lines in culture and in
most malignant tumors [1] and is detected in 85–90% of
human cancer specimens [2]. Telomerase activity is found
in most tumor types including colorectal, breast, prostate,
ovarian carcinomas and others. It also is increased in pre-
invasive lesions of the breast, such as ductal carcinoma in
situ (DCIS), suggesting that telomerase activity is activated
early in breast carcinogenesis [3]. Among the telomerase
subunits, TERT is concomitantly expressed with the activa-
tion of telomerase during cellular immortalization and
tumor progression [4], but the pattern and level of hTERT
expression are heterogeneous, with ~75% of tumors
expressing bulk hTERT mRNA levels equal to or less than
those observed in normal breast tissue; moreover, tumors
expressing higher than normal levels of hTERT mRNA are
more likely to be histopathologic grade 3, with a high frac-
tion of cells in S-phase [5].
Pre-invasive breast cancer may exhibit overexpression of
c-erbB-2 and bcl-2 oncoproteins, mutations in p53, and
alterations in cell cycle regulators [6,7]. Bcl-2 is a proto-
oncogene that codes for an inner mitochondrial mem-
brane protein [8]. The Bcl-2 gene originally was described
in follicular B-cell lymphoma, in which t (14;18) chromo-
somal translocation results in a high level of Bcl-2 gene
expression [9]. Bcl-2 overexpression in human breast can-
cer is reported to be associated with the presence of estro-
gen receptors (ER), small tumor size, low tumor grade,
and a favorable prognosis [10-17], despite contradictory
results [18,19]. Misiti et al [20] proved the role of estro-
gens and their receptors in the transcriptional regulation
of hTERT. Kyo et al [21] reported the upregulation of tel-
omerase activity in estrogen receptor (ER)-positive MCF-7
cells treated with 17-beta-estradiol [21]. Tkalogeraki et al
[22] reported telomerase activity in 72% of breast carcino-
mas, and an association was identified between telomer-
ase activity, estrogen receptors and HER-2 expression, and
histological grade and lymph node status.
We conducted the present study to determine whether an
association between telomerase activity and the expres-
sion of both molecular forms of estrogen receptor (ERα
and ERβ) and the protein bcl-2 exists. We also investigated
if telomerase function is predictive of response to chemo-
therapeutic drugs, and if it is associated with any clinical
parameters in a group of patients with infiltrating ductal
breast carcinoma.
Methods
Patients and treatment
Tumor samples were collected from breast carcinoma
patients in the Department of Oncology, and from the
Rodolfo Padilla Padilla Foundation and the National
Cancer Institute of Mexico. Informed consent for the
experimental use of samples was obtained from all
patients. Forty-four breast tumor tissues were obtained
using tru-cut biopsies. Additionally, normal human breast
tissue specimens were obtained from 2 women (aged 45
and 49) at the time of reductive mammoplasty. Each spec-
imen was sectioned immediately after surgery into two
portions; one was snap frozen for the telomerase (TRAP)
assay; and the other was fixed in 10% formalin and
embedded in paraffin for IHC, as described below.
Patients were treated with 6 cycles of FEC-based chemo-
therapy with 5-fluorouracil (500 to 600 mg/m2), epiru-
bicin (60 mg/m2), and cyclophosphamide (600 mg/m2).
Surgery consisted of modified radical mastectomy, which
was followed by radiotherapy.
Tumor response criteria
After chemotherapy, all patients were evaluated for
response by physical examination, chest radiography,
hepatic ultrasound, and computerized tomography scan.
Response to chemotherapy was classified either as 1)
complete clinical response (CR), defined as total disap-
pearance of tumor; 2) partial response (PR), defined as
>50% reduction in tumor size; 3) no-response (NR),
defined as <50% reduction in tumor size, but no clear pro-
gression; or 4) progressive disease (PD), defined as >25%
increase in the size of existing lesions or the appearance of
new tumor lesions [23].
Preparation of tissue exctract
Minced tissue samples were suspended in IX CHAPS Lysis
buffer and homogenized with a motorized pestle for 20
seconds and incubated at ice temperature for 30 min.
Samples were spined at 12000 × g for 20 min at 4°C. Aliq-
uotes of the supernatant were used for telomerase deter-
mination.
TRAP assay
Telomerase activity was measured using the TRAP method
(TRAPEZE® XL telomerase detection kit, Invitrogen, Man-
hattanville, NY), in accordance with the method proposed
by Kim et al [25]. The supernatant was poured into micro-
tubes, frozen in liquid nitrogen, and stored at -80°C.
Extracts containing 1.5–2.0 μg/μl protein were used for
telomerase assays.
Standard curve
A standard curve was generated, based upon measure-
ment of the reactions performed with a TSR8 (control
template), in order to calculate the amount of TS primersBMC Cancer 2006, 6:206 http://www.biomedcentral.com/1471-2407/6/206
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with telomeric repeats extended by telomerase in each
tumor extract. Serial dilutions (1:5) of the stock concen-
tration (0.2 amoles/μL) were prepared to obtain TSR8
concentrations of 0.04 amoles/μL, 0.008 amoles/μL, and
0.0016 amoles/μL.
Telomerase positive control and heat inactivation control
In order to validate the analysis, a HeLa cell extract from
the 1000 cells provided with the kit was prepared during
each series of reactions. Each aliquot of lysate was diluted
with CHAPS XL Buffer before use. Considering that telom-
erase is a heat-sensitive enzyme, a negative control for
every tumor sample was tested. We heated 10 μL of each
sample at 85°C for 10 min prior to TRAPEZE® XL Kit assay
performance.
Quantization of telomerase activity
The reaction products (50 μL) of the TRAP assay were
mixed with 150 μL of Buffer (10 mM Tris-HCl, pH 7.4,
0.15 M NaCl, 2 mM MgCl2). They were transferred to a
black 96-well plate to obtain maximum performance. We
used a compatible Spectrofluorophotometer plate reader
(Fluoroscan, Labsystem, Finland) to quantify the fluores-
cence value generated. A standard curve using the TSR8
template was used to validate quantitative results.
Histopathology and immunohistochemistry
Representative tissues were fixed in buffered formalin and
paraffin-embedded. Sections were cut at 5–6 μm and
placed on slides previously covered with DL-lysine. One
slide was stained with hematoxilin-eosin for analysis and
classification by 2 independent pathologists, using a 3-
tiered nuclear and histologic grading system, in accord-
ance with the Bloom and Richardson grading system. The
other unstained sections were de-paraffinized and used
for immunohistochemistry. Epitopes were retrieved by
autoclaving in 10 mM citric acid buffer, pH 6.1 for 15
min. Slides were incubated overnight with the following
primary antibodies: ΔC21 anti-human polyclonal Bcl-2;
(Santa Cruz Biotechnology, 1:100), F-10 anti-human
monoclonal ERα (Santa Cruz Biotechnology, 1:100) and
H-150 anti-human polyclonal ERβ (Santa Cruz Biotech-
nology, 1:100), all in 1% bovine serum albumin-phos-
phate buffered saline (BSA-PBS). These antibodies against
ERs have been successfully used to distinguish the two
molecular forms in experimental breast cancer [26].
Immunostaining was carried out using the Universal
DAKO LSAB2 system according to manufacturer's instruc-
tions. Alternate sections were processed omitting the pri-
mary antibody, and using instead commercial mouse IgG
cocktail (N-Universal Negative Control, DAKO N-1698
Carpinteria, CA) and rabbit IgG cocktail (N-Universal
Negative Control, DAKO N-1699 Carpinteria, CA) to gen-
erate negative controls. Immunoreactivity was estimated
in100 malignant cells to calculate the percentage positive
cells in each set. Additionally, normal breast tissue sam-
ples obtained at the time of reductive mammoplasty were
used as normal controls.
Statistical analysis
Fisher's exact test was used to determine the association
between telomerase activity and tumor size, tumor grade,
nodal status and Bcl-2 expression, using p <0.05 as level of
significance. Correlations were tested by means of Spear-
man rank correlation coefficients. The relative expressions
of estrogen receptors were analyzed using paired t-tests.
For regression analysis, the dependent variable was telom-
erase activity, again using p < 0.05 as level of significance.
Results
Patient characteristics and clinical response
Patient characteristics and tumor response are shown in
table 1. Patients had a median age of 52 years (range 27–
77 years). At the end of chemotherapy, complete response
(CR) was seen in 29 of 44 (65.9%); 15 (34.1%) had either
a partial response (PR) or no response (NR).
Telomerase activity in human breast carcinoma tissues
Telomerase activity was detected in 26 (59%) of the 44
breast examined tumors, and it was negative in the
remaining 18 (41%) samples. TRAP assay revealed that,
among the 44 breast carcinomas, the range of telomerase
activity varied greatly, ranging from 0.0 to 49.93 (Table 2).
The mean telomerase activity was 9.94 ± 18.05 TPG units
in breast cancer and none in normal tissue. We examined
the possible association between this enzyme activity and
the clinical stage of breast carcinoma. An association was
identified between telomerase activity and higher histo-
logic grade (p = 0.03; Table 3). We found no significant
correlation between telomerase activity and tumor stage.
No correlation was observed between telomerase activity
and disease course, age, or menopausal status.
Telomerase activity and response to treatment
The association between telomerase activity and response
to treatment, as a dependent variable, was also evaluated
by means of logistic regression analysis, to take into con-
sideration the effects of the other covariates investigated,
including age, cancer stage, histologic grade, status of
estrogen receptors alpha and beta, and bcl-2. Only clinical
stage reached statistical significance as an independent
marker of response to treatment, but telomerase activity
had no predictive value.
Immunohistochemistry
Positive staining for estrogen receptors alpha and beta
were primarily found in the nuclei of breast cancer malig-
nant cells. Some immunostaining was also seen in the
cytoplasm of the same cells. Neighboring cells such as
fibroblasts, macrophages, lymphocytes and endothelialBMC Cancer 2006, 6:206 http://www.biomedcentral.com/1471-2407/6/206
Page 4 of 9
(page number not for citation purposes)
cells, were unstained. The bcl-2 immunostaining was
found in the cytoplasm of cancer cells. Infiltrating lym-
phocytes showed also positive bcl-2 staining (Figure 1).
Normal breast tissue showed scattered staining in the duct
epithelium for estrogen receptors alpha and only occa-
sional nuclear staining for estrogen receptors beta. The
percentage of immunoreactivity of the ERα (54 ± 41.7%),
ERβ (28.5 ± 41%) and bcl-2 (60.8 ± 38.2%) in 44 invasive
ductal carcinomas are shown in Table 2. Differences were
found between the expression of ERα 39 (88%) and ERβ
16 (36%) (p = 0.007); the expression of bcl-2 was seen in
35 (79.5%) invasive breast carcinomas (Table 1). There
was a higher frequency of bcl-2 expression in stage II as
compared with Stage III/IV (p = 0.02; Table 4). No rela-
tionship was observed between bcl-2 and node status,
tumor size, or histological grade. However, a strong posi-
tive relationship was observed between bcl-2 and ERα,
with 26 of 35 (74.2%) bcl-2 positive tumors also being
ERα positive (p = 0.02). The expression of bcl-2 did not
correlate with ERβ.
Association between telomerase activity and expression of 
ERβ and ERα
Comparing the groups with and without ERβ expression,
the latter had lower telomerase activity (p = 0.03). In con-
trast, telomerase activity was not related to ERα expression
(p = 0.61). These overall findings indicate that ERβ is asso-
ciated with low telomerase activity.
Discussion
Our results showed that 59% of ductal breast carcinomas
had some telomerase activity confirming previous studies
in neuroblastomas, [27] lung carcinomas, hepatocellular
cancers [28] gastrointestinal cancers [29] and breast can-
cers [27]. It is known that activation of telomerase by
tumor cells can ensure survival with genomic instability.
Therefore, although telomerase might not directly act on
the carcinogenetic process it certainly is a promoter [30].
The association of telomerase activity with higher expres-
sion of Bcl-2 although not statistically significant in our
study, highlights the fact that this antiapoptotic protein
Table 1: Clinical-pathological data of 44 breast cancer patients.
Clinical Parameter Median (Range) n (%)
Age (years) 52 (27–77)
Menopausal status
Premenopausal 21 (47.7)
Postmenopausal 23 (52.3)
Clinical Stage
II 14 (31.8)
III/IV 30 (68.2)
Histologic Grade
Low 12 (27.3)
Intermediate and High 32 (72.7)
Tumoral Size
< 5 cm 21 (47.7)
> 5 cm 23 (52.3)
Axillary node status
Positive 25 (56.8)
Negative 15 (34.1)
Treatment Response
Complete Response (CR) 29 (65.9)
Partial Response (PR) or No Response (NR) 15 (34.1)
Telomerase activity
Positive 26 (59)
Negative 18 (41)
Estrogen Receptor α
Positive 39 (88)
Negative 5 (12)
Estrogen Receptor β
Positive 16 (36)
Negative 28 (64)
Bcl-2
Positive 35 (79.5)
Negative 9( 2 0 . 4 )BMC Cancer 2006, 6:206 http://www.biomedcentral.com/1471-2407/6/206
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might add another factor that promotes carcinogenesis.
We also found that the two molecular forms of ER are
expressed differently. ERα was found in 88% of cases
while ERβ was seen only in 36% of our breast cancers.
ERα and ERβ have some overlapping tissue distribution,
but also display high relative tissue-specific expression
[14-17]. Using immunochemical analyses, Roger et al [31]
found a higher percentage of ERβ positive cells in normal
mammary glands than in non-proliferative benign breast
disease (85%), proliferative disease without atypia
(18.5%) and carcinoma in situ (33.8%). In contrast, an
increase in ERα protein expression was noted during can-
cer progression. Large studies of ERβ in breast cancer show
that its expression does not correlate with absence of ERα
(-), but that some tumors and cell lines express both [32].
It has been established that ERα mRNA is increased in
breast cancer, while in normal mammary tissue the
expression of ERα mRNA is low or absent [32,33]. Others
have associated the presence of the mRNA of ERβ with
poor prognosis, positive lymph nodes, and tamoxifen
resistance [34]. We identified differences in the frequency
Table 2: Percentage of cellular immunoreactivity of the ERα, ERβ and Bcl-2 and Telomerase Activity.
Case Bcl-2% ERα%E R β% Telomerase Activity (TPG Unit)
19 46 20 1 . 3 7
2 78 63 0 49.93
3 100 10 0 1.57
4 0 13 0 4.42
54 81 00 0 . 3 5
6 0 99 98 1.45
7 100 10 98 17.07
8 70 100 90 3.53
9 100 94 100 0
10 27 0 0 0
11 0 60 0 34.7
12 0 65 89 7
13 0 10 0 17.56
14 0 10 100 0
15 100 80 60 11.96
16 98 10 0 25.47
17 100 97 71 4.75
18 93 95 100 5.24
19 0 71 0 0
20 97 50 0 19.29
21 76 78 0 11.75
22 68 65 85 25.78
23 90 100 0 41.26
24 87 91 0 7.89
25 40 100 0 0
26 89 78 10 0
27 89 99 98 0
28 85 98 40 0
29 93 0 0 0
30 94 73 0 0
31 100 90 83 0
32 10 97 73 13.65
33 99 80 0 0
34 56 89 0 4.86
35 88 75 60 0
36 0 0 0 0
37 51 10 0 7.33
38 60 9 0 12.17
39 98 10 0 13.91
40 0 0 0 0
41 25 0 0 0
42 54 98 0 2.98
43 55 100 0 0
44 63 10 0 0BMC Cancer 2006, 6:206 http://www.biomedcentral.com/1471-2407/6/206
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of expression of the estrogen receptors; beta receptor
expression was positive only in 36% of the cases, versus
88% for the alpha receptor, a percentage similar to that
reported by Shaw [35].
In chemically induced mammary cancers in rats Qiu et al
found overexpression of mRNA and protein of both
receptors as well as nuclear colocalization along with
upregulation of PCNA, suggesting a mitogenic effect [26].
Other studies have shown, however an inverse correlation
of ERβ with Ki67, a marker of cell proliferation [36].
Some clinical and in vitro studies suggest that imbalanced
ERα/ERβ expression is a common feature and could be a
critical step in estrogen-dependent tumor progression
[37]. ERβ seems to play a key role in the mitogenic action
of estrogen, by providing protection against ERα-induced
hyper-proliferation. Moreover, a number of molecular
mechanisms may explain the differential roles of ERα and
ERβ, including telomerase activity, differences in ligand
affinity and transactivation, distinct cofactor interactions,
and putative heterodimerization. Splicing variant ER iso-
forms also may be important in modulating the cellular
response [38]. The clinical value of ERβ in cancer progno-
sis and its possible usefulness as a predictor of hormone
response should be assessed in large-scale, prospective
clinical studies.
In view of our findings we could conjecture that telomer-
ase activity could be modulated by estrogen receptors,
which also might regulate the expression of bcl-2. The
identification of hTERT as a target of estrogens is a novel
finding which advances the understanding of telomerase
regulation in hormone-dependent cells, potentially impli-
cating hormones in senescence and malignant conversion
[39].
Little is known about how telomerase levels predict
responses to treatment in breast cancer. However, Taka-
hashi et al. [40] investigated the relationship between tel-
omerase activity and response to chemotherapy in
epithelial ovarian cancer patients in vivo, and reported no
significant differences between responders and non-
responders. In esophageal cancer, cell lines with high tel-
omerase activity were more sensitive to cisplatin [41,42].
In all prior studies, telomerase activity was assayed by
TRAP. The different results obtained may be ascribed, at
least in part, to technical problems related to TRAP meth-
odology. In particular, Buttitta [43] considers that one of
the main problems in the TRAP assay is that the presence
of telomerase inhibitors in the tissue extract may block the
enzyme during the TRAP assay, which might also be a
problem in the Trapeze method. The method used in this
study exhibits considerable sensibility and specificity in
the quantitative evaluation of telomerase activity, and
establishes different levels of activity. A possible explana-
tion for the technical problems that could have led to false
negative telomerase test results is the size of the tissue
sample obtained by means of a tru-cut biopsy. The ratio of
malignant cells to benign cellular elements was not quan-
tified, but it was clear that >50% of tissue was malignant
during histopathological examination.
Our study reveals a link between low levels of telomerase
activity and the absence of ERβ expression. Recent studies,
in vitro, suggest a common step in estrogen-dependent
tumor progression and telomere loss [20]. We found
lower telomerase activity in tumors that did not express
ERβ. Buttitta et al. [43] investigating the correlation
between telomerase activity and treatment response in
ovarian cancer discovered that major telomerase activity
predicted a better response to chemotherapy. Previous
studies have demonstrated that higher telomerase activity
Table 3: Correlation between molecular biomarkers and histological grade in all breast cancer specimens.
Histological grade Low Grade Intermediate and High Grade X2 P value
n (%) n (%)
Telomerase activity
Positive 8 (40) 18(75) 4.5 0.033*
Negative 12 (60) 6(25)
Bcl-2
Positive 10(83) 25(78) 0.14 0.7
Negative 2(17) 7(22)
ER alpha
Positive 12(100) 27(84) 2.11 0.15
Negative 0 (0) 5 (16)
ER beta
Positive 4(32) 12(37) 0.65 0.8
Negative 8(68) 20(63)
*Fisher's exact test (two-tailed). p significance at ≤ 0.05.BMC Cancer 2006, 6:206 http://www.biomedcentral.com/1471-2407/6/206
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In this panel we show sections of invasive ductal carcinoma of the breast incubated with different primary antibodies and  stained with the streptavidin-biotin-peroxidase complex Figure 1
In this panel we show sections of invasive ductal carcinoma of the breast incubated with different primary antibodies and 
stained with the streptavidin-biotin-peroxidase complex. A) Bcl-2 antibody is localized in the cytoplasm of malignant cells and 
infiltrating lymphocytes are also immunoreactive. B) ERα antibody is present primarily in the nuclei of malignant cells; some 
cells are negative. C) ERβ antibody is localized in the nuclei of most cancer cells. D) Negative control.(400×).
Table 4: Correlation between clinical stage and tumor biomarkers.
STAGE II (%) STAGE III/IV (%) X2 P Value
Telomerase activity
Positive 7 (50.0) 19 (63.3) 0.7 0.4
Negative 7 (50.0) 11 (36.7)
Bcl-2
Positive 14(100) 21 (70) 5.28 0.02*
Negative 0 (0) 9 (30)
Estrogen Receptor α
Positive 13(92.9) 26 (86.7) 0.36 0.55
Negative 1 (7.1) 4 (13.3)
Estrogen Receptor β
Positive 4 (28.6) 12 (40) 0.54 0.46
Negative 10(71.4) 18 (60)
*Fisher's exact test (two-tailed). p significance at ≤ 0.05.BMC Cancer 2006, 6:206 http://www.biomedcentral.com/1471-2407/6/206
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correlates with ERα expression [20]. We have not, how-
ever, found previous studies of telomerase activity in rela-
tion to the expression of ERβ in breast cancer. This study
underscores the fact that in ERβ negative tumors telomer-
ase activity is significantly reduced or abolished. These
findings may help to elucidate the mechanisms of hormo-
nal control of telomerase activity in estrogen-induced car-
cinogenesis [20].
Conclusion
We identified differences in the frequency of the expres-
sion of estrogen receptors. Estrogen receptor beta was pos-
itive in only 36% of cases while estrogen receptor alpha
was found in 88%. Our study revealed a correlation
between low levels of telomerase activity and the absence
of ERβ expression. These findings may help to elucidate
the mechanisms of hormonal control of telomerase activ-
ity, and to clarify the respective roles of estrogen-receptor
alpha and beta in breast carcinogenesis.
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